Patients' priorities in kidney stone disease

44 UK stone patients rated QoL impact at median 7/10; 82% would take prophylactic medication, but no prevention drug yet has high-quality evidence behind it.

Journal: Annals of the Royal College of Surgeons of England | Published: 2025-07-15 | Type: Survey study | PMID: 40662987 Authors: Popoola V, Wheeler G, Howles SA, Lovegrove CE (University of Oxford, UK) Funding/COI: Not listed for either

Summary

A 25-question survey of 44 kidney stone patients at a single UK tertiary centre found that pain, haematuria, and anxiety about recurrence are the dominant quality-of-life burdens — and patients badly want prevention research, not just acute management. The catch: the paper itself notes there is currently no high-quality evidence supporting any dietary or medical intervention to prevent stone recurrence. So patients are primed and willing for a drug that doesn't exist yet.

Claims

• Median self-rated QoL impact: 7.0/10 (IQR 5–9), with no significant difference between first-time and recurrent stone formers (p = 0.61)
• Top three QoL burdens: pain (n=34, 77%), haematuria (n=28, 64%), anxiety about recurrence (n=22, 50%)
• Pain was rated the single most bothersome symptom by 28 of 44 participants
• 82% (n=36) reported being "likely" or "very likely" to take prophylactic medication
• 57% (n=25) willing to commit to life-long therapy; no difference between single vs recurrent formers (p=0.97)
• Daily dosing acceptable to 30% (n=13) if recurrence risk reduced by 50%, rising to 77% (n=34) if risk reduced by 75%
• 100% expressed willingness to undergo genetic testing to support personalised medicine research
• Over one-third wanted better access to educational information about KSD

Study Quality

This is a single-centre, cross-sectional survey of 44 voluntary participants recruited in person from urology inpatient and outpatient wards via QR code poster between April 2023 and January 2024. The Joint Research Office classified it as not requiring formal ethics sponsorship. The researchers deliberately did not use the full validated Wisconsin Stone Quality of Life questionnaire to avoid survey fatigue, instead incorporating a subset of its questions — a reasonable pragmatic choice, but it limits comparability with the broader literature.

The study does what it says on the tin: it's exploratory and qualitative in intent, not a hypothesis-testing trial. Descriptive statistics are appropriate here. Wilcoxon rank sum and Pearson's chi-squared are used where comparisons are made, which is methodologically sound for this sample size. The authors are transparent about limitations and do not overclaim.

Red Flags

• N=44: Far too small for generalisable conclusions; the authors acknowledge this
• Single centre, single language: English-only, QR-code access biases toward digitally literate, English-speaking patients
• Recruitment setting bias: Patients sitting in a urology department are systematically more symptomatic than the average stone former — prevalence and severity data skew high
• No full validated QoL instrument: The partial Wisconsin Stone QoL questionnaire limits direct comparison with other datasets
• Funding undisclosed: The Oxford group's motivation (noted in-text) is to advance genetic/personalised medicine research into KSD — the survey includes questions designed to gauge patient appetite for genetic testing, which is the group's own research interest
• The survey does not separate acute vs inter-episode burden: A patient answering in the waiting room after a stone attack reads differently than one attending a routine follow-up

Strengths

• First UK-specific patient priority analysis for KSD; prior comparable work was US-based
• Honest about the evidence gap: authors state clearly that no high-quality prevention evidence currently exists
• Captures psychological burden (anxiety, 50%) alongside physical symptoms, which is often absent from outcome data
• Patient willingness data for prophylactic therapy is clinically useful framing for future trial design
• Transparent about limitations in a dedicated section

Verdict

Forty-four patients is not a dataset; it's a pilot. Nothing here should be cited as definitive evidence of anything other than "this small group at one Oxford hospital felt this way." That said, the paper is honest about its own scope, fills a genuine gap in UK-specific patient priority data, and the finding that patients want recurrence prevention above all else — for a condition where no proven prevention exists — is a useful prompt for researchers deciding where to focus. Read it as scene-setting for future trial design, not as evidence about stone disease itself.